APDS1 gene therapy - Cellectis
Latest Information Update: 31 Oct 2023
At a glance
- Originator Cellectis
- Developer Cellectis; Imagine Foundation
- Class Gene therapies
- Mechanism of Action PIK3CD protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Immunodeficiency disorders